Online first
Review paper
Published online: 2024-06-11

open access

Page views 37
Article views/downloads 23
Get Citation

Connect on Social Media

Connect on Social Media

Radiotherapy in patients with breast cancer and Li-Fraumeni syndrome — a narrative review

Joanna Huszno1, Tomasz Rutkowski1, Agata Roch-Zniszczoł1, Rafał Stec2

Abstract

Li-Fraumeni syndrome (LFS) is a rare disorder that increases the risk of many cancers, including breast cancer (BC), leukemia, soft-tissue sarcomas, central nervous system tumors, and adrenocortical carcinomas. Several previous clinical observations have shown that families with LFS are at higher risk of secondary radiotherapy-induced malignancies. This review article summarizes the available information about secondary malignancies in LFS patients who were treated with radiation therapy. A total of two electronic databases (PubMed and Web of Science) were searched using key words that included ‘Li- Fraumeni Syndrome’, ‘breast cancer’, and ‘radiotherapy’ from their inception to February 2022. Studies reporting radiosensitivity, cancer, and radiotherapy-induced secondary neoplasms were summarized. The majority of the data that were found concerned radiotherapy in patients with BC with LFS, including radiotherapy-induced malignancy. According to recommendations, radiotherapy should be used with caution and adapted to minimize the risk of secondary malignant neoplasms. The potential risk of loco-regional recurrence without radiotherapy or the long-term risk of radiation-induced malignancies must be taken into account when considering adjuvant radiotherapy for LFS and BC patients.

Article available in PDF format

View PDF Download PDF file

References

  1. Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cance Res. 1988; 48: 5358–5362.
  2. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990; 62(1): 187–192.
  3. Kumamoto T, Yamazaki F, Nakano Y, et al. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol. 2021; 26(12): 2161–2178.
  4. Aubrey BJ, Strasser A, Kelly GL. Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harb Perspect Med. 2016; 6(5).
  5. Monti P, Menichini P, Speciale A, et al. Heterogeneity of Mutations and P53 Protein Residual Function in Cancer: Does It Matter? Front Oncol. 2020; 10: 593383.
  6. Lee JM, Abrahamson JL, Kandel R, et al. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene. 1994; 9(12): 3731–3736.
  7. Schneider K, Zelley K, Nichols KE, et al. Li–Fraumeni syndrome. In: Pagon RA, Adam MP, Bird TD, et al. ed. GeneReviews. University of Washington, Seattle 1993.
  8. Chompret A, Brugières L, Ronsin M, et al. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 2000; 82(12): 1932–1937.
  9. McCuaig JM, Armel SR, Novokmet A, et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer. 2012; 11(4): 607–613.
  10. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009; 27(26): e108–9; author reply e110.
  11. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Guidelines Version 1.2023 Li-Fraumeni Syndrome Management.
  12. Guha T, Malkin D. Inherited Mutations and the Li-Fraumeni Syndrome. Cold Spring Harb Perspect Med. 2017; 7(4).
  13. Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016; 122(23): 3673–3681.
  14. Page M, McKenzie J, Bossuyt P, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021: n71.
  15. Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat. 2018; 167(2): 417–423.
  16. Cirauqui B, Morán T, Estival A, et al. Breast Cancer Patient with Li-Fraumeni Syndrome: A Case Report Highlighting the Importance of Multidisciplinary Management. Case Rep Oncol. 2020; 13(1): 130–138.
  17. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998; 90(8): 606–611.
  18. Masciari S, Dillon DA, Rath M, et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat. 2012; 133(3): 1125–1130.
  19. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012; 118(4): 908–913.
  20. Li X, Chen X, Wen L, et al. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA. Thorac Cancer. 2020; 11(7): 1861–1868.
  21. Zhou F, Zhang Y, Xu X, et al. Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53. Cancer Cell Int. 2018; 18: 118.
  22. Liu H, Murphy CJ, Karreth FA, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov. 2018; 8(3): 354–369.
  23. Lindahl T, Landberg G, Ahlgren J, et al. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis. 2004; 25(3): 375–380.
  24. Feeley LP, Mulligan AM, Pinnaduwage D, et al. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol. 2014; 27(4): 554–561.
  25. Wilson JRF, Bateman AC, Hanson H, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 2010; 47(11): 771–774.
  26. Morton LM, Onel K, Curtis RE, et al. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book. 2014: e57–e67.
  27. Mullenders L, Atkinson M, Paretzke H, et al. Assessing cancer risks of low-dose radiation. Nat Rev Cancer. 2009; 9(8): 596–604.
  28. Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018; 36(2): 85–94.
  29. Boyle JM, Spreadborough A, Greaves MJ, et al. The relationship between radiation-induced G(1)arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations. Br J Cancer. 2001; 85(2): 293–296.
  30. Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015; 33(21): 2345–2352.
  31. Limacher JM, Frebourg T, Natarajan-Ame S, et al. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer. 2001; 96(4): 238–242.
  32. Ferrarini A, Auteri-Kaczmarek A, Pica A, et al. Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53. Fam Cancer. 2011; 10(2): 187–192.
  33. Le AN, Harton J, Desai H, et al. Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Res Treat. 2020; 181(1): 181–188.
  34. Salmon A, Amikam D, Sodha N, et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol). 2007; 19(7): 490–493.
  35. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998; 90(8): 606–611.
  36. Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010; 5: 104.
  37. Barbosa OV, Reiriz AB, Boff RA, et al. Angiosarcoma in previously irradiated breast in patient with Li-Fraumeni syndrome. A case report. Sao Paulo Med J. 2015; 133(2): 151–153.
  38. Nandikolla AG, Venugopal S, Anampa J. Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature. Breast Cancer (Dove Med Press). 2017; 9: 207–215.
  39. Henry E, Villalobos V, Million L, et al. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Canc Netw. 2012; 10(8): 939–942.
  40. Petry V, Bonadio RC, Cagnacci AQ, et al. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer. 2020; 19(1): 47–53.
  41. Kast K, Krause M, Schuler M, et al. Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. BMC Cancer. 2012; 12: 217.
  42. Wong P, Han K. Lack of toxicity in a patient with germline TP53 mutation treated with radiotherapy. Curr Oncol. 2014; 21(2): e349–e353.
  43. Hendrickson PG, Luo Y, Kohlmann W, et al. Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study. Cancer Med. 2020; 9(21): 7954–7963.
  44. Frebourg T, Bajalica Lagercrantz S, Oliveira C, et al. European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020; 28(10): 1379–1386.
  45. Chung CS, Yock TI, Nelson K, et al. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys. 2013; 87(1): 46–52.
  46. Paganetti H, Moteabbed M, Athar B, et al. SU-E-T-258: Assessment of Radiation Induced Second Cancer Risks in Proton Therapy and IMRT for Organs inside the Main Radiation Field. Med Phys. 2012; 39(6Part13): 3762–3763.
  47. Niemantsverdriet M, van Goethem MJ, Bron R, et al. High and low LET radiation differentially induce normal tissue damage signals. Int J Radiat Oncol Biol Phys. 2012; 83(4): 1291–1297.
  48. Eley JG, Friedrich T, Homann KL, et al. Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy. Int J Radiat Oncol Biol Phys. 2016; 95(1): 279–286.
  49. Thariat J, Chevalier F, Orbach D, et al. Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromes. Lancet Oncol. 2021; 22(12): e562–e574.
  50. Iwasaki T, Mizumoto M, Numajiri H, et al. Re-irradiation using proton therapy for radiation-induced secondary cancer with Li-Fraumeni syndrome: A case report and review of literature. J Cancer Res Ther. 2020; 16(6): 1524–1527.
  51. Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Ann Oncol. 2020; 31(6): 674–696.
  52. Tung NM, Boughey JC, Pierce LJ, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020; 38(18): 2080–2106.
  53. Trombetta MG, Dragun A, Mayr NA, et al. ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer. Pract Radiat Oncol. 2020; 10(4): 235–242.